Condiciones de salud que chirimoya puede ayudar a apoyar.
Vitamin D3 (cholecalciferol) is the specific form of vitamin D studied in acne clinical trials, with 1,000 IU/day associated with improvement in inflammatory acne lesions in deficient patients. It reduces sebum production, inhibits C. acnes, and modulates immune response. Deficiency is significantly more prevalent in acne patients than controls.
Vitamin D3 (cholecalciferol) is the active supplemental form of vitamin D evaluated in clinical trials for allergic rhinitis. It modulates Th1/Th2 immune balance, reduces IL-5 and IL-13, and promotes regulatory T cells. Meta-analyses confirm adjuvant vitamin D3 supplementation reduces total nasal symptom scores and IgE levels in AR patients. It is a component of clinically validated combination nutraceuticals (with quercetin and Perilla) that demonstrated 39% greater symptom improvement over standard antihistamine therapy in seasonal AR.
Vitamin D3 (cholecalciferol) is the biologically preferred form of vitamin D, with receptors expressed in Leydig cells of the testes. A placebo-controlled RCT (Pilz et al.) demonstrated that D3 supplementation significantly increased total and free testosterone in men versus placebo over one year. Its relevance to andropause is highest in men with established vitamin D deficiency, a common finding in aging male populations.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D studied for arterial health. It inhibits the renin-angiotensin system, reduces vascular inflammation, and improves endothelial function. A 2022 network meta-analysis of 22 RCTs specifically included cholecalciferol among supplements assessed for arterial stiffness reduction.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, with a recognized role in bone health, chondrocyte regulation, and immune modulation relevant to OA and RA. The Arthritis Foundation lists it as studied for OA; NCCIH cites its role in bone health and immune regulation in arthritis. A 2018 meta-analysis found vitamin D3 supplementation reduced RA disease activity scores.
Vitamin D3 (cholecalciferol) is the animal-derived form of vitamin D with well-documented roles in asthma management, including reducing exacerbation frequency and modulating Th2-driven airway inflammation. A 12-week RCT in adult asthmatics found 125 µg/day vitamin D3 significantly improved FEV1:FVC ratio vs. placebo. Meta-analyses support its adjunct role in asthma treatment.
Vitamin D3 (cholecalciferol) specifically is the form most studied and used in autoimmune disease prevention and treatment. The VITAL trial used 2000 IU/day D3, reducing new autoimmune disease incidence by 22%. It regulates T-regulatory cells, suppresses adaptive immune overactivation, and VDR-mediated signaling is relevant across MS, RA, T1D, and SLE.
Vitamin D3 (cholecalciferol) is the biologically preferred form of vitamin D for supplementation in back pain. A randomized placebo-controlled trial studied 300,000 IU intramuscular vitamin D3 for discogenic pain in lumbar disc herniation. A comparative clinical trial found vitamin D3 supplementation significantly reduced VAS pain and IL-6 in adults with LBP versus untreated control, comparable to ginger extract.
Vitamin D3 (cholecalciferol) is the supplemental form used to raise serum 25-hydroxyvitamin D, which has been associated with Bell's palsy risk and severity in a 2025 systematic review and meta-analysis (BMC Neurology). As a neuro-immunomodulator, vitamin D3 may reduce facial nerve inflammation and support recovery through immune regulation and neuroprotective pathways.
Vitamin D3 (cholecalciferol), the animal-derived and skin-synthesized form of vitamin D, is more potent than D2 in raising serum 25(OH)D levels. RCTs consistently show that vitamin D3 combined with calcium reduces bone loss, particularly at the hip and spine, and it is endorsed by WHO, NIH, and major osteoporosis guidelines as the preferred supplemental form for bone health.
Vitamin D3 (cholecalciferol) is the biologically active form of vitamin D cited for bursitis-related inflammation. It regulates cytokines, inhibits NF-κB and prostaglandins, and correlates inversely with inflammatory markers. A meta-analysis of RCTs confirmed reduction of high-sensitivity CRP with supplementation. Cited by pain management sources for bursitis.
Vitamin D3 is the cholecalciferol form of vitamin D used in supplementation trials for CTS. Vitamin D deficiency is an independent risk factor for CTS, and several studies specifically using vitamin D3 supplementation have demonstrated improved pain, functional status, and nerve conduction in CTS patients. A 2024 RCT confirmed electroneuromyographic and clinical benefits.
Vitamin D3 (cholecalciferol) is the preferred supplemental form used to correct vitamin D deficiency in celiac disease, as endorsed by the ACG 2013 and UK NICE 2015 guidelines. Malabsorption of fat-soluble vitamins including D3 is a hallmark of untreated CeD. Combined D3 and calcium supplementation is specifically recommended when GFD alone fails to normalize bone mineral density.
Vitamin D3 deficiency is consistently associated with increased risk of atopic dermatitis, asthma, and allergic sensitization in children. A Spanish birth cohort (n=2525) found higher child 25(OH)D3 at age 4 was associated with significantly lower odds of atopic eczema from ages 4–9 (aOR=0.90 per 5 ng/ml). Small RCTs show vitamin D3 supplementation reduces eczema severity and decreases asthma exacerbation risk in children. A 2022 systematic review and meta-analysis of pediatric RCTs evaluated vitamin D supplementation specifically in children with allergic diseases.
Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D for children, more effectively raising serum 25-hydroxyvitamin D than vitamin D2. It supports calcium absorption, bone mineralization, and dental development. Studies show it is the preferred choice for correcting vitamin D deficiency in pediatric populations.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for children's immune health. Pediatric immune support protocols specifically recommend vitamin D3 year-round at 400–1,000 IU/day. D3 is more effective than D2 at raising serum 25(OH)D levels and demonstrates superior immunomodulatory activity in respiratory infection prevention trials.
Vitamin D3 (cholecalciferol) is the preferred form of vitamin D in children's multivitamins. It is the naturally occurring, most bioavailable form, confirmed present in essentially all major branded children's MVMs (ChildLife, Kirkman, and others) per authoritative label surveys. NIH ODS-established RDA is 600 IU/day for children.
Vitamin D3 (cholecalciferol) is the most bioavailable and clinically studied form of vitamin D for chronic pain. RCTs show supplementation reduces pain in deficient individuals with fibromyalgia and chronic musculoskeletal pain. It suppresses neuroinflammatory cytokines TNF-α, IL-17 and modulates central pain sensitization.
Substantial observational and epidemiological evidence links low vitamin D3 status to increased risk of cognitive decline and dementia in older adults, supported by plausible neurobiological mechanisms. However, randomized controlled trials have produced largely null or mixed results, meaning supplementation has not been conclusively proven to prevent or slow cognitive decline in vitamin D-sufficient populations. The overall picture is one of an active, contested scientific relationship with promising signals but insufficient interventional proof.
Cholecalciferol (vitamin D3) is the primary supplemental form evaluated in respiratory infection trials. Meta-analyses including the 2017 Cochrane analysis (25 RCTs, >11,000 participants) confirm it reduces ARI risk, with greatest benefit in deficient individuals. Jolliffe et al. 2021 IPD meta-analysis (46 RCTs, >75,000 participants) confirmed benefit. It induces cathelicidin and defensins in respiratory mucosa.
Vitamin D3 (cholecalciferol) has been specifically tested in a double-blind RCT in UC patients with vitamin D deficiency, showing increased serum levels and improvements in quality of life and disease activity indices at doses of 2,000–4,000 IU/day over 90 days. VDR-mediated signaling supports intestinal barrier integrity and reduces colonic inflammation.
Vitamin D3 (cholecalciferol) is the specific bioactive form of vitamin D that crosses the blood-brain barrier and has been evaluated in TBI and mTBI recovery clinical studies. It reduces neuroinflammation, supports BDNF expression, and correlates with improved cognitive and functional outcomes when supplemented post-TBI. The same clinical and mechanistic evidence base applying to vitamin D applies specifically to D3 as it is the predominant form administered in relevant trials.
Vitamin D3 (cholecalciferol) is the directly studied form of vitamin D in COPD RCTs. An RCT in 120 COPD patients compared 50,000 IU/day vitamin D3 against calcitriol and placebo, finding clinical improvement in treated groups. A 2024 systematic review confirmed vitamin D3 supplementation improved FEV1 in COPD patients. Deficiency of D3 is strongly associated with increased exacerbation risk.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for correcting the highly prevalent deficiency in Crohn's disease. A double-blind crossover RCT confirmed significantly raised serum vitamin D in CD patients with D3 supplementation. Clinical authorities rate it as having the strongest combined evidence (deficiency correction plus therapeutic benefit) among CD supplements.
Vitamin D3 (cholecalciferol) supplementation has been specifically studied in Cushing's disease patients, who have significantly higher rates of vitamin D deficiency than matched controls. A clinical study (Nutrients 2022; n=50 active CD patients) found that vitamin D deficiency severity correlated with urinary free cortisol levels. Six weeks of cholecalciferol supplementation (150,000 IU load) significantly improved insulin sensitivity, raised 25(OH)D, lowered PTH, and reduced total cholesterol in CD patients. The study recommends vitamin D supplementation as a standard part of CD management.
Vitamin D3 (cholecalciferol) is the more bioavailable form of vitamin D studied in depression clinical trials. Its deficiency is consistently linked to depressive disorders, and supplementation is recommended as a Grade A adjunct for MDD by CANMAT/WFSBP 2022 guidelines. It regulates serotonin synthesis, neuroinflammation, and HPA axis function.
Vitamin D3 supplementation has specific RCT evidence for atopic dermatitis. A 2020 RCT in 86 children with severe AD found D3 1600 IU/day significantly reduced EASI scores versus placebo. A 2024 meta-analysis of 11 RCTs confirmed overall significant reduction in AD severity with vitamin D supplementation.
A meta-analysis of 14 studies found serum 25(OH)D3 significantly lower in DED patients versus controls (WMD −5.93; p<0.001). Clinical trials show vitamin D3 supplementation improves TBUT, Schirmer, and OSDI. When combined with lutein, zeaxanthin, and curcumin in an 8-week RCT (n=155), it met primary DED endpoints (p<0.001 both measures).
Vitamin D3 (cholecalciferol) is the form of vitamin D most studied in atopic dermatitis, with a meta-analysis of nine RCTs demonstrating significant SCORAD improvement. It modulates filaggrin expression, Th2 immune dysregulation, and antimicrobial peptide production—all central to eczema pathogenesis.
Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D. Low vitamin D3 is associated with impaired oocyte quality, reduced ovarian reserve, and poorer IVF outcomes. An RCT combining vitamin D3 with myo-inositol, folic acid, and melatonin significantly improved IVF clinical pregnancy rates (42% vs. 24%).
Vitamin D3 (cholecalciferol) is the form most commonly used in clinical studies evaluating vitamin D supplementation for FM. Evidence base is the same as for vitamin D: meta-analyses confirm association of deficiency with FM symptom severity and significant pain reduction with supplementation in deficient patients. The 2025 systematic review and meta-analysis found significant FM pain reduction (SMD −0.85 to −0.87) with vitamin D supplementation.
Vitamin D3 (cholecalciferol) is the more bioavailable form of vitamin D, essential for musculoskeletal health, chondrocyte function, and muscle physiology relevant to joint mobility. Deficiency correlates with worsened OA outcomes and impaired physical function. A 2025 network meta-analysis of 39 RCTs for knee OA included vitamin D among evaluated supplements, and supplementation improves muscle strength and physical performance tests.
Vitamin D3 (cholecalciferol) is the biologically active form studied in ADHD pediatric research. Multiple studies document lower vitamin D3-related serum markers in children with ADHD. RCTs demonstrate improvement in attention and hyperactivity with D3 supplementation. A 2024 network meta-analysis of 48 ADHD pediatric studies (n=3,650) ranked vitamin D among the most effective nutritional interventions.
Vitamin D3 (cholecalciferol) is the more bioavailable form of vitamin D evaluated in RCTs for periodontal disease as an adjunct to periodontal therapy. Clinical trials evaluating specific vitamin D doses (500–2000 IU/day) have predominantly used cholecalciferol. Its bone-protective, anti-inflammatory, and immunomodulatory properties are directly relevant to alveolar bone preservation and periodontal inflammation control.
Vitamin D3 (cholecalciferol) is the active supplemental form linked to hair follicle cycling via VDR signaling in dermal papilla and keratinocytes. Deficiency is associated with multiple forms of alopecia, and correcting deficiency supports hair follicle anagen initiation. Clinical evidence parallels that of vitamin D, as D3 is the predominant supplement form studied.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, acting via follicular vitamin D receptors to regulate hair cycling. Deficiency is associated with alopecia areata and androgenetic alopecia. Clinical guidelines recommend correction of documented deficiency in patients with non-scarring hair loss.
Vitamin D3 (cholecalciferol) is the most bioavailable and biologically active form of supplemental vitamin D, with the VITAL trial (n=25,871, 2000 IU/day, 5.3 years) demonstrating reduced cancer mortality and autoimmune disease. It is linked to telomere protection, immune aging support, bone density maintenance, and reduced all-cause mortality in older adults.
Vitamin D3 (cholecalciferol) is the animal-derived, most bioavailable form of vitamin D, synthesized in the skin by UV-B radiation and used in most clinical supplementation trials in children. It is the preferred form in pediatric supplementation guidelines (AAP, EFSA) specifically because it is more effective than D2 at raising serum 25(OH)D. Its role in bone growth, calcium homeostasis, and the GH/IGF-1 axis firmly establishes it as a critical nutrient for healthy childhood growth and development.
Vitamin D3 (cholecalciferol) is the preferred form of vitamin D for supplementation and shares the same hearing-health evidence base as vitamin D generally. Deficiency correlates with higher hearing loss risk, increased tinnitus loudness, and worse outcomes in sudden SNHL. Correcting deficiency with D3 has shown clinical benefit for tinnitus in RCTs.
Vitamin D3 has an extensively studied relationship with cardiovascular health, supported by substantial epidemiological, mechanistic, and clinical trial data. Observational studies consistently link low vitamin D levels to higher risks of hypertension, atherosclerosis, heart failure, and myocardial infarction. Mechanistically, vitamin D3 modulates the renin–angiotensin system, endothelial function, inflammation, and cardiomyocyte calcium handling. However, large RCTs have generally not confirmed a significant reduction in major cardiovascular events with supplementation in unselected populations, and evidence strength remains mixed.
Cholecalciferol (vitamin D3) is the most clinically effective form of vitamin D for reducing thyroid autoantibodies in Hashimoto's thyroiditis. A 2021 meta-analysis confirmed that vitamin D3 specifically (not generic vitamin D) significantly reduced TPOAb titers (SMD −1.48; p=0.006) in HT patients. It works by modulating Treg/Th17 immune balance and reducing pro-inflammatory cytokines.
Vitamin D3 has IBS-specific RCT and meta-analytic evidence. A 2025 umbrella review (Nutr Rev, 175 RCTs) identified vitamin D3 as improving IBS symptom severity. An RCT in 74 IBS-D patients with vitamin D deficiency found significant IBS symptom severity and IL-6 reduction with 50,000 IU/week for 9 weeks versus placebo. Vitamin D deficiency is disproportionately prevalent in IBS patients.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D and is specifically studied in IBD clinical trials. Deficiency is prevalent in IBD patients and associated with disease activity; D3 supplementation reduces inflammatory markers and may maintain CD remission in clinical trials.
Vitamin D3 derivatives are listed in StatPearls as a recognized treatment escalation option for KP beyond first-line keratolytics, for patients who do not respond to initial therapy. This is mechanistically supported by vitamin D3's role in regulating keratinocyte differentiation relevant to KP's follicular hyperkeratosis pathology.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D with documented effects on intestinal barrier function via VDR-mediated tight junction protein upregulation. A Mayo Clinic RCT (NCT01640496) specifically studied vitamin D3's effects on colonic permeability and mucosal tight junction protein expression in ulcerative colitis. Multiple authoritative gut health reviews identify vitamin D3 as one of the top evidence-supported supplements for intestinal barrier support.
Vitamin D3 (cholecalciferol) is the specific form of vitamin D studied in AMD research and included in AMD clinical trial supplement formulations. Observational studies associate adequate vitamin D3 status with lower AMD risk, and a Japanese case-control study linked low vitamin D intake to neovascular AMD. Vitamin D3 at 2000 IU/day was included in the AMD-specific multivitamin RCT (NCT03946085). Its anti-inflammatory and anti-VEGF properties are mechanistically relevant to AMD.
Vitamin D3 regulates hair follicle cycling via vitamin D receptor (VDR) signaling; VDR mutations cause alopecia. A 2024 systematic review (PubMed 39440586, 49 studies) identified vitamin D as one of four critical micronutrients whose deficiency is consistently associated with AGA risk and whose supplementation shows potential benefit for hair growth.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D, with evidence for mast cell stabilization via VDR-dependent suppression of IgE-mediated degranulation. A 2016 PubMed study confirmed VDR signaling is required for mast cell stability, and deficiency causes activation. D3 raises serum 25(OH)D more effectively than D2, making it the clinically recommended form for MCAS-related vitamin D protocols.
Vitamin D3 (cholecalciferol) is the most bioavailable supplemental form of vitamin D, directly relevant to postmenopausal bone health and osteoporosis prevention. A 2025 systematic review confirmed its benefits alongside calcium for postmenopausal osteoporosis management. Postmenopausal women are specifically identified as a population at high risk for vitamin D deficiency.
Substantial clinical and epidemiological evidence links vitamin D3 deficiency to metabolic syndrome (MetS), with observational meta-analyses consistently showing an inverse association between serum 25(OH)D and MetS risk. Randomized controlled trials (RCTs) and their meta-analyses suggest vitamin D3 supplementation may modestly reduce fasting glucose, triglycerides, and insulin resistance, particularly in deficient individuals. However, causality remains contested: some meta-analyses find no significant improvement in metabolic parameters, leaving the observed association partly attributable to confounding. The evidence base is scientific but the therapeutic benefit is not firmly established.
Vitamin D receptors are present in mitochondrial membranes, and vitamin D deficiency impairs mitochondrial ATP production and respiratory chain activity. Evidence shows vitamin D modulates mitochondrial function through regulation of mitochondrial fission/fusion dynamics and ROS production, with deficiency linked to widespread mitochondrial dysfunction.
Vitamin D3 (cholecalciferol) is the most bioavailable form of supplemental vitamin D and three times more potent than D2 at raising serum 25(OH)D. It has documented roles in skeletal muscle VDR signaling, inflammation modulation, and calcium handling, with indirect evidence supporting recovery in deficient athletes.
Vitamin D3 (cholecalciferol) is the specific form studied in MG clinical investigations. A pilot study of 800 IU/day vitamin D3 in 13 MG patients showed 22% increases in serum levels and 38% muscle fatigue improvement. Vitamin D3 appears to regulate Treg cells in MG patients, and its deficiency is consistently associated with MG prevalence across cohort and cross-sectional studies.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for osteoporosis prevention, more potent at raising serum 25(OH)D than D2. It is universally included in osteoporosis management guidelines. RCTs confirm its role, especially when combined with calcium, in increasing BMD and reducing fracture risk in older adults.
Vitamin D3 (cholecalciferol) is the primary supplemental form studied in relation to overactive bladder and urinary incontinence. A meta-analysis found vitamin D deficiency increased OAB risk more than 4-fold, and supplementation reduced urinary incontinence risk by 66%. Vitamin D3 receptors exist in bladder muscle and pelvic floor tissue, and correcting deficiency has shown clinical urinary symptom improvements.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, with consistent evidence of deficiency in Parkinson's disease patients. Observational studies link higher serum 25(OH)D3 levels with lower PD incidence. Small RCTs of D3 supplementation have been conducted in PD with modest motor improvement signals.
Vitamin D3 (cholecalciferol) is the preferred, most bioavailable form of vitamin D for supplementation and is specifically used in perimenopausal care for bone health, mood, immune function, and overall hormone regulation during the menopausal transition. European Menopause Society guidelines support its use.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D and is specifically recommended for picky eaters deficient in vitamin D due to avoidance of dairy and fatty fish. It is more effective than D2 at raising serum 25-hydroxyvitamin D levels. Children's multivitamins for picky eaters commonly include D3.
The most biologically active supplemental form of vitamin D, vitamin D3 (cholecalciferol) is the form used in the majority of clinical trials demonstrating immune modulation and reduced risk and duration of respiratory illness. It specifically supports post-illness immune restoration by upregulating antimicrobial peptides and modulating T-cell responses.
Cholecalciferol (vitamin D3) is the most bioavailable supplemental form of vitamin D and is specifically studied in COVID-19 and post-viral recovery contexts. It supports immune modulation and reduces inflammatory markers. Clinical protocols for long COVID from the VA and published integrative medicine reviews recommend vitamin D3 as part of post-viral recovery.
Vitamin D3 (cholecalciferol) is the preferred form of vitamin D in postnatal supplements, shown in RCTs to correct postpartum maternal and infant deficiency when taken at 6,000 IU/day. It supports immune recovery, bone health, mood stability, and breastmilk vitamin D content. Breastfeeding women face heightened risk of deficiency due to transfer of D3 into milk.
Vitamin D3 (cholecalciferol) is the most bioavailable and clinically preferred form of vitamin D for prenatal supplementation, demonstrating superior ability to raise serum 25(OH)D levels compared to D2. Used in the majority of prenatal RCTs, it supports fetal skeletal development, reduces preeclampsia risk, and supports neonatal immune and neurodevelopmental outcomes. ACOG and NICE specifically reference vitamin D3 in their prenatal supplementation contexts.
Vitamin D3 (cholecalciferol) and its analogue calcipotriol are established in the treatment of psoriasis. Calcipotriol is a first-line topical therapy. Oral vitamin D3 supplementation has been evaluated in RCTs including a randomized double-blind placebo-controlled trial for chronic plaque psoriasis published in J Dermatolog Treat (2018), with a 2023 meta-analysis of RCTs showing PASI improvement.
Vitamin D3 (cholecalciferol) is the supplemental form most frequently studied in chronic urticaria RCTs. A 2025 systematic review confirms that interventional studies using D3 supplementation demonstrated symptom improvement and reduced disease severity in chronic urticaria. Its mechanism involves mast cell stabilization and reduction of histamine-driven inflammation.
Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D, with superior efficacy over D2 for raising serum 25(OH)D. It suppresses Th17-driven RA inflammation and promotes regulatory T cells. Multiple RCTs of vitamin D3 supplementation in RA patients show improvements in DAS28, pain, and inflammatory markers.
Vitamin D3 (cholecalciferol) is the bioactive supplemental form of vitamin D, identified in multiple authoritative clinical reviews as a key nutrient for sciatic nerve pain. It reduces neuroinflammation, supports myelin health, and addresses deficiency linked to worsening sciatica. A randomized clinical trial used D3 in a combination treatment for discogenic sciatica.
Multiple peer-reviewed studies and meta-analyses show that vitamin D deficiency is significantly prevalent in adolescent idiopathic scoliosis (AIS) patients, negatively correlating with bone mineral density and positively correlating with Cobb angle severity. A 2023 meta-analysis (6 studies, 1,428 patients) found vitamin D insufficiency in ~36% and deficiency in ~41% of AIS patients. A Romanian randomized interventional trial (2017–2020) demonstrated that daily supplementation with vitamin D (2,000 IU), calcium, and melatonin positively affected curve progression in children aged 7–16 with idiopathic scoliosis.
Vitamin D3 (cholecalciferol) is the endogenous form of vitamin D produced in skin via UVB and the primary supplemental form studied for SAD. Reduced winter sunlight causes declining vitamin D3 production, and low serum 25(OH)D is consistently associated with SAD. Clinical evidence parallels that for vitamin D broadly: mixed results across RCTs, with NCCIH not currently supporting D3 monotherapy as an effective SAD treatment.
Vitamin D3 plays an immunomodulatory role in respiratory allergy, with epidemiological evidence linking deficiency to increased allergic rhinitis severity and a dedicated clinical trial (Bakhshaee et al., Eur Arch Oto-Rhino-Laryngol, 2019) showing supplementation improved AR symptoms. It promotes Treg development, suppresses Th2 polarization, and reduces IgE production.
Vitamin D3 (cholecalciferol) is the primary form studied in relation to OSA. Meta-analyses (29 studies, N=6,717) confirm lower 25(OH)D in OSA patients, with severity inversely correlated with vitamin D status. Sustained deficiency is associated with a 25–28% increased hazard for developing OSA in a large retrospective cohort. Mechanistically, vitamin D3 may support upper airway dilator muscle function and reduce OSA-associated inflammation.
Vitamin D3 (cholecalciferol) is the primary supplemental form of vitamin D studied in testosterone RCTs. It acts via Leydig cell vitamin D receptors to stimulate testosterone synthesis and reduce SHBG. A 12-month double-blind RCT found supplementation with approximately 3,300 IU/day significantly increased total and free testosterone versus placebo in vitamin D-insufficient men.
Vitamin D3 (cholecalciferol) is the specific form studied in a double-blind RCT for vitamin D-deficient TMD patients in combination with splint therapy, showing significant improvements in mouth opening and pain scores. It was also included in a TMD nutraceutical RCT formulation (Boswellia, magnesium, tryptophan, B2, D3). Deficiency is associated with higher TMD incidence in cohort studies.
Vitamin D3 (cholecalciferol) is the active supplemental form of vitamin D, supporting calcium absorption and regulating mineral homeostasis required for enamel remineralization. Evidence links adequate D3 status to reduced caries risk and improved enamel mineralization, with D3 receptors identified on ameloblasts and odontoblasts.
Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D used in URTI clinical research. The landmark 2017 BMJ meta-analysis (25 RCTs, n=11,321) found D3 supplementation significantly reduced acute respiratory infection incidence, with greatest benefit in severely deficient individuals using daily/weekly dosing.
Vitamin D3 deficiency is associated with increased occurrence and recurrence of benign paroxysmal positional vertigo (BPPV). A landmark multicenter RCT (Jeong et al., 2020, Neurology, n=1050) demonstrated vitamin D3 400 IU plus calcium carbonate 500 mg twice daily for 1 year significantly reduced BPPV annual recurrence rate (IRR 0.76, p<0.001). A meta-analysis of five studies confirmed significant BPPV recurrence reduction (fixed-effects RR=0.68, p<0.0001) with vitamin D supplementation.
Vitamin D3 (cholecalciferol) is the most biologically active supplemental form of vitamin D, with established roles in modulating both innate and adaptive antiviral immune responses. Clinical evidence supports its role in reducing respiratory viral infection risk, particularly in deficient individuals. It induces cathelicidins and defensins and modulates T cell responses.
Vitamin D3 deficiency is significantly more common in vitiligo patients, confirmed by multiple meta-analyses. It promotes melanocyte tyrosinase activity and differentiation via melanocyte vitamin D receptors and has immunomodulatory effects on autoreactive T cells. High-dose supplementation (35,000 IU/day) produced significant repigmentation in a published case series, and expert dermatologists recommend repletion when levels are insufficient.
Volver